Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Columbia University

Neither a doctor nor a teaching hospital

Research payments

$27,088,323

1,048 payments

Through program year 2025, Columbia University is reported as receiving $27,088,323 in research payments, across 1,048 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,785,984 170
2024 Research $2,003,968 145
2023 Research $4,529,929 98
2022 Research $2,785,424 131
2021 Research $5,321,770 175
2020 Research $5,737,449 150
2019 Research $2,923,800 179

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $7,659,747 350 payments
  2. AstraZeneca Pharmaceuticals LP $7,472,546 40 payments
  3. E.R. Squibb & Sons, L.L.C. $3,542,884 64 payments
  4. Merck Sharp & Dohme Corporation $2,834,109 80 payments
  5. Genzyme Corporation $805,545 6 payments
  6. Sanofi US Services Inc. $731,001 11 payments
  7. XVIVO Perfusion Inc. $507,011 10 payments
  8. Fresenius USA Marketing, Inc. $306,947 5 payments
  9. Celgene Corporation $282,257 5 payments
  10. Allergan Inc. $273,413 85 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer $3,590,473 76 payments
  2. Cure GN research Agreement $2,392,854 1 payment
  3. A Phase 1 First in Human Dose Escalation Study of JNJ63898081 in Subjects with Advanced Stage Solid Tumors $990,827 18 payments
  4. Phase 2 study of combination chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative treatment of loco regional gastric or GE junction adenocarcinoma. $897,411 1 payment
  5. Radiomics Pilot in NSCLC $750,000 1 payment
  6. Multi Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor Selumetinib in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor $513,526 2 payments
  7. DeLiver $507,011 10 payments
  8. Phase 2 study of combination chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative treatment of loco regional gastric or GE junction adenocarcinoma. $502,064 7 payments
  9. A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for Metastatic Castration Resistant Prostate Cancer $494,478 22 payments
  10. Genomic Uniformed-Screening Against Rare Disease in All Newborns $449,686 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $102,984 22 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record